Skip to main content

Table 6 Treatment-related adverse events (unit: cases)

From: Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study

Treatment-related adverse events-no(%)a

ALL

Grade 3

Grade 4

COPD

Non-COPD

COPD

Non-COPD

COPD

Non-COPD

Fatigue

10(33.3)

13(29.5)

2(6.7)

1(2.3)

0

0

Gastrointestinal reaction

8(26.7)

10(22.7)

1(3.3)

1(2.3)

0

0

Leukocytopenia

13(43.3)

18(40.9)

1(3.3)

3(6.8)

2(6.7)

3(6.8)

Anemia

5(16.7)

8(18.2)

0

0

0

0

Neutropenia

6(20.0)

10(22.7)

1(3.3)

1(3.3)

2(6.7)

3(6.8)

Rash

3(10.0)

1(2.3)

0

0

0

0

Hypothyroidism

2(6.7)

3(6.8)

1(3.3)

1(2.3)

0

0

Elevated transaminase

3(10.0)

5(11.4)

0

0

0

0

Alopecia

3(10.0)

6(13.6)

0

0

0

0

Abnormal myocardial enzyme

1(3.3)

0

0

0

0

0

  1. aIncluded are events reported between the first neoadjuvant dose and 30 days after the last neoadjuvant dose